BOUNDLESS BIO, INC. (BOLD) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$23.13M*; Operating income -$24.38M; Depreciation and amortization $1.26M*.
- 2026-03-31: Basis Reported; EBITDA -$14.19M*; Operating income -$14.47M; Depreciation and amortization $284.00K.
- 2025-09-30: Basis Reported; EBITDA -$14.84M*; Operating income -$15.15M; Depreciation and amortization $310.00K*.
- 2025-06-30: Basis Reported; EBITDA -$16.74M*; Operating income -$17.06M; Depreciation and amortization $317.00K*.
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$23.13M* | -$24.38M | $1.26M* | (m) | (m) | $38.00K* | -$20.97M* | (m) | $13.97M | (m) | (m) |
| 2026-03-31 | Reported | -$14.19M* | -$14.47M | $284.00K | (m) | (m) | $8.00K | -$14.97M | (m) | $9.73M | (m) | (m) |
| 2025-09-30 | Reported | -$14.84M* | -$15.15M | $310.00K* | (m) | (m) | $15.00K* | -$10.20M* | (m) | $10.67M | (m) | (m) |
| 2025-06-30 | Reported | -$16.74M* | -$17.06M | $317.00K* | (m) | (m) | $48.00K* | -$11.83M* | (m) | $12.22M | (m) | (m) |
| 2025-03-31 | Reported | -$17.02M* | -$17.34M | $317.00K | (m) | (m) | $59.00K | -$14.53M | (m) | $12.14M | (m) | (m) |
| 2024-09-30 | Reported | -$18.45M* | -$18.71M | $262.00K* | (m) | (m) | $483.00K* | -$13.27M* | (m) | $14.09M | (m) | (m) |
| 2024-06-30 | Reported | -$19.13M* | -$19.39M | $265.00K* | (m) | (m) | $1.50M* | -$16.24M* | (m) | $14.73M | (m) | (m) |
| 2024-03-31 | Reported | -$16.62M* | -$16.88M | $263.00K | (m) | (m) | $83.00K | -$15.78M | (m) | $13.13M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$14.95M | (m) | (m) | (m) | $151.00K* | -$12.19M* | (m) | $11.64M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$13.96M | (m) | (m) | (m) | $128.00K* | -$10.89M* | (m) | $11.07M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$12.09M | (m) | (m) | (m) | $86.00K | -$12.09M | (m) | $9.50M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | -$62.30M* | -$63.55M | $1.25M | (m) | (m) | $546.00K | -$46.66M | (m) | $44.84M | (m) | $0.00 |
| 2024-12-31 | Reported | -$72.18M* | -$73.27M | $1.09M | (m) | (m) | $2.54M | -$60.84M | (m) | $55.27M | (m) | $0.00 |
| 2023-12-31 | Reported | -$53.84M* | -$54.80M | $957.00K | (m) | (m) | $633.00K | -$46.85M | (m) | $42.64M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |